Poster Session A - Sunday Afternoon
Kyle McCall
Texas A&M Health Science Center College of Medicine
Dallas, TX
SIR-Spheres® (SS) | TheraSpheres® (TS) | |
Procedures | 147 | 63 |
Gender | ||
Male | 73% | 62% |
Female | 27% | 38% |
Race | ||
Caucasian | 56% | 52% |
African American | 20% | 21% |
Hispanic or Latino | 21% | 22% |
Asian | 3% | 5% |
Etiology of Liver Disease | ||
Hepatitis C | 55% | 46% |
Non-alcoholic Steatohepatitis (NASH) | 24% | 25% |
Other | 21% | 29% |
Tumor Characteristics | ||
Number of Lesions (median) | 3 | 2 |
Total Tumor Diameter (median) | 6.4 cm | 5.1 cm |
Bilobar Tumors | 61% | 31% |
Portal Vein Thrombosis | 46.9% | 25.4% |
Model for End-Stage Liver Disease (MELD) Score | ||
Score (median) | 9 | 8 |
Barcelona Clinic Liver Cancer (BCLC) Stage | ||
Stage 0 | 1% | 3% |
Stage A | 11% | 13% |
Stage B | 45% | 43% |
Stage C | 38% | 35% |
Stage D | 5% | 6% |
Associated Symptoms Pre-Treatment | ||
Ascites | 16% | 16% |
GI Bleed | 16% | 22% |
Hepatic Encephalopathy | 17% | 17% |
Associated Symptoms Post-Treatment | ||
Ascites | 29% | 16% |
GI Bleed | 3% | 2% |
Hepatic Encephalopathy | 8% | 0% |
Modified Response Evaluation Criteria in Solid Tumors (mRECIST) | ||
Complete Response | 37% | 49% |
Partial Response | 21% | 25% |
Stable Disease | 21% | 10% |
Progressive Disease | 20% | 16% |